CMPP Asthma Practice Test 2025 – Complete Exam Prep

When managing severe persistent asthma, a high-dose inhaled corticosteroid (ICS) combined with a long-acting beta-agonist (LABA) and a leukotriene receptor antagonist (LTRA) is often recommended. This combination is effective in addressing the underlying inflammation and bronchoconstriction associated with severe asthma.

High-dose ICS plays a crucial role in controlling chronic inflammation in the airways, thereby reducing the frequency of exacerbations and improving overall respiratory function. The addition of LABA provides long-lasting bronchodilation, which helps to relieve symptoms such as wheezing and shortness of breath. LTRAs contribute to asthma management by blocking leukotriene receptors, thereby reducing leukotriene-mediated inflammation and bronchoconstriction.

Using this combination therapy allows for a more comprehensive approach to managing severe persistent asthma, targeting different aspects of the condition and maximizing control over symptoms. It is typically preferred over monotherapy with just one type of medication. In contrast, options like oral corticosteroids alone or just inhaled corticosteroids may not provide sufficient control for someone with very severe persistent asthma.